U.S. markets open in 1 hour 31 minutes
  • S&P Futures

    3,818.00
    -28.00 (-0.73%)
     
  • Dow Futures

    30,830.00
    -252.00 (-0.81%)
     
  • Nasdaq Futures

    13,317.75
    -77.75 (-0.58%)
     
  • Russell 2000 Futures

    2,116.50
    -22.00 (-1.03%)
     
  • Crude Oil

    51.76
    -1.37 (-2.58%)
     
  • Gold

    1,842.70
    -23.20 (-1.24%)
     
  • Silver

    25.25
    -0.61 (-2.36%)
     
  • EUR/USD

    1.2167
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.1090
    0.0000 (0.00%)
     
  • Vix

    23.42
    +1.84 (+8.53%)
     
  • GBP/USD

    1.3660
    -0.0071 (-0.51%)
     
  • USD/JPY

    103.7500
    +0.2450 (+0.24%)
     
  • BTC-USD

    31,533.88
    +1,050.13 (+3.44%)
     
  • CMC Crypto 200

    627.08
    +17.09 (+2.80%)
     
  • FTSE 100

    6,659.60
    -55.82 (-0.83%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

Passage Bio to Present at Piper Sandler 32nd Annual Healthcare Conference

Passage Bio
·2 min read

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., chief executive officer of Passage Bio, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference, taking place December 1 – 3, 2020.

The fireside chat is now available for registered attendees to view on-demand through the duration of the event using the following link: https://pipersandler.zoom.us/rec/play/d_yM-Fctp6pbiQ-Vk47m18Ij75qQ0rl4RBw1uXq4WfE7AZg1ncYcoGi-T24oaKz4JC1ScCtz5Pxw_IE.0ErrIDIHIiQNwRST

A recording of the fireside chat is also available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com and will remain active for 30 days.

About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with unparalleled access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Investors:
Sarah McCabe and Zofia Mita
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
zofia.mita@sternir.com

Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com